Riskpilot← Back to searchSign inGet full accessSaiph Therapeutics Oy
OYDissolvedY-tunnus 1811614-0Orionintie 1Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 20030 employees
Revenue 2024
EUR 173K
EBITDA margin
0.0%
+127% vs 2023
Equity ratio
99.8%
Financial strength
Net profit 2024
EUR 21
+127% vs 2023
| Revenue | EUR 173K | — |
| EBITDA | EUR 21 | +127% |
| Net profit | EUR 21 | +127% |
| Total assets | EUR 3,4M | +16298% |
| Equity | EUR 3,4M | +42892% |
| Employees | 0 | — |
Legal name
Saiph Therapeutics Oy
Y-tunnus number
1811614-0
Legal form
Osakeyhtiö
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
11. helmikuuta 2003
Share capital
EUR 8 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen ja toimitusjohtaja yhdessä sekä hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääke-, bioteknologia-, diagnostiikka- ja kemianteollisuuden sekä terveydenhoitoalan tuotteiden, laitteiden, välineiden, tarvikkeiden ja palvelujen tuotanto ja valmistus, myynti, maahantuonti ja maastavienti, lääkekehitys ja muu näihin liittyvä liiketoiminta sekä kaikkiin edellä mainittuihin aloihin liittyvä tutkimus- ja tuotekehitystoiminta, tieteellisten ja teknologisten palvelujen myynti, teknologian siirto ja lisensiointi sekä suunnittelu ja konsultointi. Yhtiö voi toimintaansa varten hallita, omistaa ja antaa vuokralle kiinteistöjä sekä omistaa, myydä ja hallita osakkeita ja muita arvopapereita.
Address
Orionintie 1
Phone
+3580104261
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 173 |
| Staff expenses | — | — | −0 | −0 | −0 |
| EBITDA | −0 | −0 | 0 | −0 | 0 |
| Depreciation & amort. | — | — | −0 | −0 | −0 |
| EBIT | −0 | −0 | 0 | −0 | 0 |
| Net financials | — | — | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | 0 | −0 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −0 | −0 | 0 | −0 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 | 21 | 7 | 21 | 3 438 |
| Equity | 6 | 6 | 8 | 8 | 3 432 |
| Long-term debt | 1 | 15 | 15 | 15 | 0 |
| Short-term debt | — | — | 0 | 0 | 6 |
| Total debt | 1 | 15 | 15 | 15 | 6 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
IT Confidential Clerk | Confidential Clerk | 2019 |
MT Chief Executive Officer | Chief Executive Officer | 2025 |
AJ Confidential Clerk | Confidential Clerk | 2010 |
| Former (5) | ||
KP | Audit | 2018 – 2023 |
JI Confidential Clerk | Confidential Clerk | 2010 – 2024 |
PK Confidential Clerk | Confidential Clerk | 2010 – 2019 |
OH Chief Executive Officer | Chief Executive Officer | 2003 – 2025 |
KM Confidential Clerk | Confidential Clerk | 2010 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairperson | 2022 | |
| Board of Directors | 2025 | |
| Former (1) | ||
| Chairperson | 2018 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Orion Oyj
Saiph Therapeutics Oy Board members of Saiph Therapeutics Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kimmo Petteri Antonen | Audit | 0 companies |
| Ilkka Tapio Rämänen | Confidential Clerk | 0 companies |
| Mikko Tapani Kemppainen | Chief Executive Officer | 0 companies |
| Jari Ilmari Karlson | Confidential Clerk | 0 companies |
| Anu Johanna Karvonen | Confidential Clerk | 0 companies |
| Pirjo Kyllikki Göös | Confidential Clerk | 0 companies |
| Olli Heikki Huotari | Chief Executive Officer | 0 companies |
| Kari Martti Kantola | Confidential Clerk | 0 companies |
| Aino Anna Liisa Hurme | Chairperson | 0 companies |
| René Kristian Lindell | Board of Directors | 0 companies |
| Timo Antero Lappalainen | Chairperson | 0 companies |